Epidemiological and clinical features of primary liver cancer: an analysis of 236 patients

Zhao RongRong; Deng YongDong; Yuan Hong

doi:10.3969/j.issn.1001-5256.2016.08.021

Issue 8

Aug. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(8): 1538-1542

PDF( 1487 KB)

Epidemiological and clinical features of primary liver cancer: an analysis of 236 patients

DOI: 10.3969/j.issn.1001-5256.2016.08.021

Department of Infectious Diseases,The First Hospital of Lanzhou University

Received Date: 2016-02-14
Published Date: 2016-08-20

Abstract

Abstract

Objective To investigate the epidemiological and clinical features of patients with primary liver cancer( PLC). Methods A retrospective analysis was performed for the clinical data of 236 patients with complete information who were admitted to The First Hospital of Lanzhou University and diagnosed with PLC for the first time form August 2012 to August 2014,and their epidemiological and clinical features were analyzed. The chi- square test was used for comparison of categorical data between groups. Results Among the 236 PLC patients,there were 198 male patients( 83. 9%) and 38 female patients( 16. 1%),and the patients aged 41- 60 years has the highest incidence rate( 58. 5%,138 /236). Nineteen patients had a family history of liver cancer,28 had a history of heavy drinking,34 were complicated by type 2 diabetes,and 44 were complicated by hypertension. Among these patients,232( 98. 3%) developed PLC on the basis of chronic liver disease,and 4( 1. 7%) had no chronic liver disease. There were 207 patients( 87. 7%) with chronic HBV infection,and most of them had HBe Ag- negative infection. Fourteen patients( 5. 9%) had chronic HCV infection,5( 2. 1%) had HBV / HCV co- infection,and 6( 2. 5%) had chronic alcoholic hepatitis. Among the 212 patients with HBV infection,51( 24. 1%) had HBe Ag- positive chronic hepatitis B,and 95( 44. 8%) had HBe Ag- negative chronic hepatitis B; there was significant difference in HBV DNA level between the two groups( χ2= 40. 687,Ρ = 0. 001). Among all the PLC patients,104 had an alpha- fetoprotein( AFP) level of > 400 IU / ml,48 had an AFP level of 200- 400 IU / ml,and 84 had an AFP level of < 200 IU / ml; 154( 62. 3%) had a single lesion,and 72( 30. 5%) had multiple lesions; most( 72. 7%) of patients with a single lesion had the single lesion in the right lobe,and the proportions of patients with multiple lesions in the right lobe and in both lobes accounted for 58. 3% and 41. 7%,respectively. Among the 80 PLC patients with pathological results,most( 85%) had hepatocellular carcinoma. Conclusion PLC has certain distribution patterns in sex,age of onset,family history of liver cancer,etiology,tumor position,number of tumors,and pathological histology. The factors involved in the development and progression of PLC need in- depth investigation,in order to develop good control strategies. Moreover,the association of PLC with chronic metabolic diseases such as diabetes and hypertension awaits further investigation.
- liver neoplasms,
- epidemiology studies

FullText(HTML)

References(26)

References

[1]GUIU B,MINELLO A,COTTET V,et al.A 30-year,population-based study shows improved management and prognosis of hepatocellular carcinoma[J].Clin Gastroenterol Hepatol,2010,8(11):986-991.

[2]NORDENSTEDT H,WHITE DL,EL-SERAG HB.The changing pattern of epidemiology in hepatocellular carcinoma[J].Dig Liver Dis,2010,42(Suppl 3):s206-s214.

[3] JEMALA,BRAFY,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.

[4]CHEN WQ,ZHENG RS,ZENG HM,et al.Report of cancer incidence and mortality in China,2011[J].China Cancer,2015,24(1):1-10.(in Chinese)陈万青,郑荣寿,曾红梅,等.2011年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,24(1):1-10.

[5] FERLAY J,SHIN HR,BRAY F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.

[6]BOSCH FX,RIBES J,DAZ M,et al.Primary liver cancer:worldwide incidence and trends[J].Gastroenterology,2004,127(5 Suppl 1):s5-s16.

[7]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[8] SHARIFF MI,COX IJ,GOMAA AI,et al.Hepatocellular carcinoma:current trends in worldwide epidemiology,risk factors,diagnosis and therapeutics[J].Expert Rev Gastroenterol Hepotol,2009,3(4):353-367.

[9]KENG VW,LARGAESPADA DA,VILLANUEVA A.Why men are at higher risk for hepatocellular carcinoma?[J].J Hepatol,2012,57(2):453-454.

[10] KIM SS,HWANG JC,LIM SG,et al.Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients:comparison between compensated and decompensated cirrhosis[J].Am J Gastroenterol,2014,109(8):1223-1233.

[11]CENI E,MELLO T,GALLI A.Pathogenesis of alcoholic liver disease:role of oxidative metabolism[J].World J Gastroenterol,2014,20(47):17756-17772.

[12] MERCER KE,HENNINGS L,RONIS MJ.Alcohol consumption,Wnt/β-catenin signaling,and hepatocarcinogenesis[J].Adv Exp Med Biol,2015,815:185-195.

[13] LI D,TANG H,HASSAN MM,et al.Diabetes and risk of pancreatic cancer:a pooled analysis of three large case-control studies[J].Cancer Causes Control,2011,22(2):189-197.

[14]XU CX,ZHU HH,ZHU YM.Diabetes and cancer:associations,mechanisms,and implications for medical practice[J].World J Diabetes,2014,5(3):372-380.

[15] HEMMINKI K,LI X,SUNDQIST J,et al.Risk of cancer following hospitalization for type 2 diabetes[J].Oncologist,2010,15(6):548-555.

[16]JI SW,WANG JB.The risk analysis of type 2 diabetes mellitus to the development of primary liver carcinoma[J].Chin Hepatol,2007,12(3):168-170.(in Chinese)季尚玮,王江滨.2型糖尿病对原发性肝癌发病的危险性分析[J].肝脏,2007,12(3):168-170.

[17] BROOKES MJ,COOPER BT.Hypertension and fatty liver:guilty by association?[J].J Hum Hypertens,2007,21(4):264-270.

[18]TURATI F,EDEFONTI V,TALAMINI R,et al.Family history of liver cancer and hepatocellular carcinoma[J].Hepatology,2012,55(5):1416-1425.

[19]VINCIGUERRA M,VEYRAT-DUREBEX C,MOUKIL MA,et al.PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappa Bp65/m TOR-dependent mechanism[J].Gastroenterology,2008,134(1):268-280.

[20] CHEN CJ,YANG HI,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA,2006,295(1):65-73.

[21]PAPATHEORIDIS GV,CHAN HL,HANSEN BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy[J].J Hepatol,2015,62(4):956-967.

[22]TESTINO G,LEONE S,BORRO P.Alcohol and hepatocellular carcinoma:a review and a point of view[J].World J Gastroenterol,2014,20(43):15943-15954.

[23]ZHANG F,SHAO YF,XU Y,et al.The relationship between HBV replicative markers and hepatocarcinogenesis[J].Chin J Gen Surg,2006,21(1):1-3.(in Chinese)张峰,邵永孚,许杨,等.乙肝病毒活跃复制与肝细胞癌发生的相关性研究[J].中华普通外科杂志,2006,21(1):1-3.

[24]EL-SERAG HB,RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132(7):2557-2576.

[25]DUAN WB,WANG QW,ZHANG B,et al.Clinical analysis of 92cases of hepatic cholangiocarcinoma and 384 cases of hepatocellular carcinoma[J].China J Modern Med,2009,19(24):3786-3789.(in Chinese)段文斌,王群伟,张斌,等.胆管细胞性肝癌临床归属之我见(附92例胆管细胞性肝癌与384例肝细胞性肝癌的临床分析)[J].中国现代医学杂志,2009,19(24):3786-3789.

[26]DONG ZY,ZENG Q,WANG J,et al.Effect of primary tumor location on postoperative recurrence for patients with hepatocellular carcinoma[J].Cancer Res Prevent Treat,2012,39(5):542-546.(in Chinese)董忠谊,曾钦,王剑,等.肝癌首发部位对患者术后复发的影响[J].肿瘤防治研究,2012,39(5):542-546.

Relative Articles

[1]	Chunshan FU, Xiaomei FENG, Xiumei CHI, Jun ZI, Junqi NIU, Zhuancai ZHANG. Epidemiological situation of hepatitis D in the gathering area of Mongolian population in Inner Mongolia Autonomous Region of China[J]. Journal of Clinical Hepatology, 2023, 39(5): 1076-1080. doi: 10.3969/j.issn.1001-5256.2023.05.012
[2]	Shan SHAN, Lianhui ZHAO, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA. Definition, etiology, and epidemiology of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 14-16. doi: 10.3969/j.issn.1001-5256.2021.01.003
[3]	Xiaoyun LI, Jieting TANG. Epidemiology of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2510-2514. doi: 10.3969/j.issn.1001-5256.2021.11.002
[4]	WANG WenHui, DUAN XuHua, LI Hao, LI FengYao, JU ShuGuang, WANG ManZhou, REN JianZhuang, HAN XinWei. Effect of arsenic trioxide-loaded CalliSpheres beads in the treatment of rabbits with VX2 liver tumor[J]. Journal of Clinical Hepatology, 2020, 36(12): 2730-2734. doi: 10.3969/j.issn.1001-5256.2020.12.018
[5]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[6]	Yan TaoTao, Li Juan, Fu Shan, Zhang Rou, Ren DanFeng, Zhu Li, Liu JinFeng, He YingLi, Zhao YingRen, Zhang XinXin. Composition and changing trend of the etiologies of liver failure in Shaanxi Province,China[J]. Journal of Clinical Hepatology, 2020, 36(2): 387-390. doi: 10.3969/j.issn.1001-5256.2020.02.031
[7]	Chen Xu, Su MingHua, Jiang JianNing, Liu ZhiHong, Wei Qi, Wu FeiFei, Zhou Yi, Teng ChunLing. Epidemiological features of positive anti-HCV among the HIV-infected population in Guangxi,China[J]. Journal of Clinical Hepatology, 2020, 36(1): 88-93. doi: 10.3969/j.issn.1001-5256.2020.01.020
[8]	Shen Tao, Huang Xin, Wang YuYa, Zhuang Hui. Current status of epidemiological studies on drug-induced liver injury in China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1152-1155. doi: 10.3969/j.issn.1001-5256.2018.06.002
[9]	Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
[10]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[11]	Fang ZiYan, Huang Long, Li Gong. Research progress in radiotherapy for liver tumors reported in 2013 ASTRO Annual Meeting[J]. Journal of Clinical Hepatology, 2014, 30(4): 383-385. doi: 10.3969/j.issn.1001-5256.2014.04.025
[12]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[13]	Tang ZhaoYou. 21st century:challenges facing the clinical research of liver cancer[J]. Journal of Clinical Hepatology, 2012, 28(4): 241-242.
[14]	Chen Hong, Wang Zhi, Wu Jian. Circulating tumor cells of hepatocellular carcinoma and their clinical implications[J]. Journal of Clinical Hepatology, 2011, 27(8): 796-800.
[16]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(95)

1.	熊晗，彭海燕. 基于肝主疏泄探讨原发性肝癌的治则治法. 光明中医. 2024(07): 1322-1325 .
2.	黄澜，朱宗国，冯涛. 血清甲胎蛋白、PIVKA-Ⅱ、GGT、GGT/ALT检测对早期原发性肝癌的诊断价值. 临床和实验医学杂志. 2024(07): 749-752 .
3.	鄢岗辉，陈小华，吴鑫. 增强CT与MRI鉴别诊断肝硬化与原发性肝癌的价值. 医学信息. 2024(09): 145-148 .
4.	赵璇，顾向前，蔡兵，周晓雯. 老年原发性肝癌微波消融术后复发危险因素的多元COX回归分析. 肝胆外科杂志. 2024(02): 122-125 .
5.	宋春荣，南然，刘永刚，李京涛，闫曙光，魏海梁，席奇，寇小妮. 益脾养肝方对肝郁脾虚证原发性肝癌TACE患者bFGF、VEGF、AFP-L3及免疫功能影响. 辽宁中医药大学学报. 2022(01): 80-84 .
6.	游家生，吕秀金，郭伟娟. 动态增强MRI与CT对乙型肝炎肝硬化背景下原发性肝癌的诊断价值. 海南医学. 2022(01): 79-82 .
7.	张东东，张明顼，孙立倩. 肝动脉化疗栓塞联合微波消融术治疗原发性肝癌合并动静脉瘘的临床疗效. 中国医疗设备. 2022(03): 56-59+70 .
8.	刘君，呼圣娟，郭建阳，唐宁，刘晗，王雪，李艳玲，冶正财. 乙型肝炎病毒相关性肝硬化肝癌与非肝硬化肝癌临床特点对比分析. 临床消化病杂志. 2022(02): 115-119 .
9.	许文翼，金大业，吴倩倩，夏青，马霁波. 小柴胡汤联合常规疗法对原发性肝癌TACE术后患者免疫功能及生活质量的影响. 新中医. 2022(13): 151-154 .
10.	陈丽娜，樊雪峰，赵晓瑞. 甲磺酸阿帕替尼联合DEB-TACE治疗中晚期肝细胞癌的效果及其对血生化指标、生存期及生存率的影响. 辽宁医学杂志. 2022(04): 104-107 .
11.	马来福. 动态增强计算机断层扫描和数字减影血管造影技术联合血清甲胎蛋白水平诊断小肝癌的准确性分析. 当代医学. 2022(19): 58-61 .
12.	张学政，吴冬冰，张学娟，吴冬寒，谭琰. 术前肝功能储备预测肝癌手术患者预后价值的倾向性匹配研究. 现代肿瘤医学. 2022(24): 4486-4490 .
13.	杨英兰，王妍妍. 乙型病毒性肝炎肝硬化患者原发性肝癌发生的危险因素. 中国卫生工程学. 2022(06): 945-947 .
14.	潘悦. MRI和CT动态增强扫描在原发性肝癌诊断中的应用价值. 医学信息. 2021(07): 88-91 .
15.	刘剑芳. 基于IEES支持法护理对肝胆外科患者术后加速康复的应用效果. 辽宁医学杂志. 2021(02): 91-93 .
16.	李朋娟，赖丽，李红阁. 加减龙胆泻肝汤对原发性肝癌TACE术后栓塞综合征患者肝功能和生活质量的影响. 广州中医药大学学报. 2021(05): 876-879 .
17.	加静，朱超凡，艾绍庆. 原发性肝癌患者介入治疗预后的影响因素分析. 中国肿瘤临床与康复. 2021(04): 414-416 .
18.	林辉雄，王琳，周悦乔，刘志强，林川杰. Hsa_circ_0003998调控miR-218-5p/Wnt/β-catenin通路对肝癌细胞增殖、迁移和侵袭的影响. 中西医结合肝病杂志. 2021(05): 435-439 .
19.	李春鸣，余更生，崔恩铭，饶建，雷芳勇，周树权. 影像组学特征对肝癌放疗敏感性的影响分析. 中国医学创新. 2021(23): 155-159 .
20.	张玉莲. 以配偶为中心的支持应对对肝切除患者心理弹性及创伤后成长的影响. 河南医学研究. 2021(29): 5547-5550 .
21.	庞康清，马洪德，杨汝磊，庞国宏. 血清PTX3在肝细胞癌中的表达及临床意义. 肿瘤防治研究. 2021(12): 1078-1081 .
22.	刘英娜. 混合型肝癌的CT及MRI影像学表现分析. 中国CT和MRI杂志. 2020(02): 88-91 .
23.	邹强生，魏贞，蒋婷，李姗. C1orf 61对肝细胞肝癌细胞迁移能力的影响及作用机制研究. 河北医药. 2020(11): 1633-1636 .
24.	黄培宁，程吉云，余贤恩，韦凯扬，彭乃宝，蓝常明. 肝硬化后肝癌患者的临床特征及肝硬化进展为肝癌的危险因素. 广西医学. 2020(12): 1494-1497 .
25.	黄文薮，郭永建，黄敬君，周静文，梁礼聪，吴镜强. 肝动脉化疗栓塞联合阿帕替尼治疗原发性肝癌的安全性和有效性分析. 中华介入放射学电子杂志. 2020(03): 247-251 .
26.	甘郑宁，马梦雪，严小娟. 能谱CT成像碘物质定量分析在肝细胞癌鉴别诊断中的应用价值. 肝脏. 2020(07): 695-698 .
27.	朱少功，王维伟，汤高枫，彭江涛，张德志. 肝癌疼痛与血清HIF-1及VEGF表达的相关性研究. 中国实用医刊. 2020(15): 12-16 .
28.	田海龙，汤洁. 临床护理路径对肝癌介入治疗患者疼痛程度、生活质量及预后的影响. 国际护理学杂志. 2020(10): 1847-1850 .
29.	尹秀芬，罗革，黄伶俐，孙甜，罗彩玉. 医护一体化在肝癌行部分肝切除患者加速康复中的应用研究. 中外医学研究. 2020(33): 111-113 .
30.	冯亮杰，乔师师. 肝动脉化疗栓塞术(TACE)对原发性肝癌患者的血常规影响及相关因素分析. 河南外科学杂志. 2020(06): 28-30 .
31.	施凤，雷宇鹏. 他汀类药物对2型糖尿病患者发生肝细胞癌风险的影响. 临床肝胆病杂志. 2019(01): 161-163 . 本站查看
32.	浦沛广，邹喜明. 原发性肝癌876例综合归纳分析. 世界最新医学信息文摘. 2019(15): 77+79 .
33.	齐杰，高战强，刘术昌，焦健，张化冰，冯磊. 磁共振扩散加权成像与螺旋CT分别联合血清AFP对早期原发性肝癌诊断价值的对比分析. 实用癌症杂志. 2019(02): 285-288 .
34.	姜业臻，李超，王宇峰，涂康生，刘青光. ZNF217在肝细胞癌中的表达及对肿瘤侵袭的影响. 实用癌症杂志. 2019(03): 349-353 .
35.	兰勇，张阳，邢人伟，陈明. Tim-3对肝癌干细胞自我更新能力的调控以及对TGF-β1/smad4通路的影响. 中国药师. 2019(03): 425-429 .
36.	刘海涛，马晓萍，郭亮. TACE联合三维适形放疗治疗原发性肝癌的效果及对免疫功能的影响. 临床医学研究与实践. 2019(10): 17-18+22 .
37.	张海光，苗亚敬，李世龙，张宝，司玉广. 复方苦参注射液联合体外高频热疗治疗晚期肝癌腹腔积液的疗效分析. 辽宁中医杂志. 2019(04): 779-782 .
38.	李蕾. 肝癌术后肺部感染的手术室相关因素分析及护理. 实用临床护理学电子杂志. 2019(15): 57-58 .
39.	赵华. 四君子汤联合雷替曲塞和奥沙利铂治疗晚期肝癌的疗效及对免疫功能的影响. 现代中西医结合杂志. 2019(15): 1630-1633+1644 .
40.	朱丽娜，谢宝杰，殷风华，李智岗. DynaCT对肝转移瘤介入治疗具有指导意义. 基因组学与应用生物学. 2019(05): 2265-2269 .
41.	程华，龙书美，王喆攀. 原发性肝癌患者术后睡眠障碍的影响因素探究. 中国医学前沿杂志(电子版). 2019(05): 102-105 .
42.	吴丹，朱建奎，张艳，张杨帆，王献伟. 化学发光免疫法检验原发性肝癌肿瘤生物标志物的应用价值研究. 实用癌症杂志. 2019(06): 1002-1004 .
43.	张晓平. 原发性肝癌患者流行病学与临床特点分析. 现代养生. 2019(12): 121-122 .
44.	周正，郑伟. SH2B1对肝癌细胞增殖、凋亡及Akt/mTOR通路的影响. 医学综述. 2019(12): 2473-2478 .
45.	郭俊霞，魏晓华. 乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析. 陕西医学杂志. 2019(07): 850-852 .
46.	钟长军，王秀. 原发性肝癌中西医结合治疗及危险因素研究现状. 锦州医科大学学报. 2019(04): 106-108 .
47.	王霞，郭莹盈，曾献东. TSGF、CEA、AFP、GGT和AFU联合检测对肝癌的诊断价值. 实用癌症杂志. 2019(08): 1294-1296 .
48.	方云，刘波，芦东徽，陈慧慧，朱捷. YB-1基因沉默对肝癌细胞化学治疗敏感性的影响及可能机制. 中国肝脏病杂志(电子版). 2019(02): 15-20 .
49.	武慧峰. 认知行为干预对老年原发性肝癌患者的影响. 实用中西医结合临床. 2019(08): 169-171 .
50.	孟菁菁，贾建民. AFP-L3、Fer、TSGF联合检测对原发性肝癌的诊断价值. 实用癌症杂志. 2019(09): 1402-1404 .
51.	李成业，孙丽娟. TAE和TACE治疗原发性肝癌的效果及对肝功能分级的影响. 检验医学与临床. 2019(18): 2634-2636+2639 .
52.	杨红梅，尹强，徐宏宇，刘琴，孙瑛，肖嫔，邓玉兰. 以家庭为中心的护理路径在儿童肝脏肿瘤PICC置管中的应用. 肿瘤药学. 2019(04): 691-695 .
53.	杨明镇，赵逵. 哇巴因体外逆转肝癌耐药Bel-7402/ADM细胞的实验研究. 中国当代医药. 2019(26): 60-62 .
54.	杨昭，张岚. 大黄■虫丸合消瘿汤对老年晚期原发性肝癌患者生存率的影响. 辽宁中医杂志. 2019(10): 2098-2101+2237 .
55.	叶赛. 外周血TNF-α和hs-CRP水平在肝癌患者预后评估中的价值. 中国卫生工程学. 2019(05): 740-742 .
56.	张高明，杨慧林，王智，阎雄，代鸿华. 血清INF-γ、sIL-2R、IL-12在原发性肝癌中的表达及临床意义. 国际检验医学杂志. 2019(21): 2650-2653 .
57.	薛麟，肖翔. 自体CIK细胞肝动脉灌注联合放化疗对原发性肝癌患者免疫功能及生活质量的影响. 实用癌症杂志. 2019(10): 1625-1628 .
58.	谢青云，雷泽华，高峰畏，蒋康怡，刘宇. 甲磺酸阿帕替尼联合callispheres载药微球-肝动脉化疗栓塞术(DEB-TACE)治疗中晚期肝细胞癌的临床疗效分析. 肝胆外科杂志. 2019(02): 95-99 .
59.	翁志成，彭建扬，吴伟达，张春生，林群，潘喜鹏. 阿帕替尼联合S-TACE治疗中晚期原发性肝癌的疗效及安全性评价. 癌症进展. 2019(22): 2666-2669 .
60.	郑笑笑. 血清AFP、TK1、DKK1水平联合检测对原发性肝癌诊断效能的影响. 首都食品与医药. 2019(24): 116-117 .
61.	朱鸷翔，沈松鹤，李荟苹，赵森，王志学. CT与磁共振成像对原发性肝癌患者经导管肝动脉化疗栓塞术后复查诊断准确率的对比研究. 实用医学影像杂志. 2019(05): 522-524 .
62.	张建男，于雯，王丽丽，秦洁，尹荣荣，张梅，曹文学. 腹部术后改良助行器在原发性肝癌患者术后早期活动中的应用研究. 护士进修杂志. 2018(06): 568-570 .
63.	周步琴，张强，蒲宝平. 超声造影联合CT增强扫描在诊断早期肝癌合并肝硬化中的应用. 国外医学(医学地理分册). 2018(02): 172-174 .
64.	樊永强，董胜利. 靶向药物治疗肝细胞癌的最新进展. 临床肝胆病杂志. 2018(02): 424-428 . 本站查看
65.	郭晓笛，孙莎莎，李文东，申燕军，孙巍，丁晓燕，陈京龙. 140例BCLC分期C期原发性肝癌患者的临床特征及预后影响因素分析. 临床肝胆病杂志. 2018(07): 1456-1461 . 本站查看
66.	刘洪金，鲍春梅，白文林，李因茵，荣光华，陆荫英，陈艳，刘泽，程家敏，曾珍. 原发性肝癌发生感染性并发症的危险因素分析. 临床肝胆病杂志. 2018(05): 1033-1037 . 本站查看
67.	龚静青，曹端荣，李晓鸣，邹桂华. miR-204在原发性肝细胞癌中的表达及评价. 热带医学杂志. 2018(06): 750-754 .
68.	钱赟达，楼晓军，沈灵娜，陈洁，李玲. 膈下逐瘀汤联合精准肝动脉化疗栓塞术治疗中晚期原发性肝癌临床研究. 新中医. 2018(09): 140-143 .
69.	谢立民. 自拟疏肝健脾方联合洛铂介入栓塞治疗原发性肝癌的疗效. 深圳中西医结合杂志. 2018(11): 32-34 .
70.	张建男，蒋国庆，刘燕金. 医护一体化宣教模式在肝癌患者术后早期离床活动中的应用研究. 实用临床医药杂志. 2018(12): 23-26 .
71.	许为霞，胡燊. 肝癌术后肺部感染的手术室相关因素分析及护理. 中外医学研究. 2018(08): 116-118 .
72.	吴昊. 肝脏增强CT技术与肝脏MRI技术诊断肝癌的准确率. 影像研究与医学应用. 2018(13): 249-250 .
73.	尚韬. 四种治疗方法对肝癌破裂出血患者近期止血效果及生存时间的影响. 浙江中西医结合杂志. 2018(02): 133-134 .
74.	邹瑞. 原发性肝癌患者血清HCY、AFU、CA199联合检测的临床价值. 肝脏. 2018(05): 421-423 .
75.	张平武，方林. GP73联合AFP-L3检测在低浓度甲胎蛋白肝癌患者诊断中的应用. 肝脏. 2018(09): 804-806 .
76.	周世繁，孙宏新. 康莱特联合索拉非尼对晚期肝癌患者T细胞亚群及生存质量的影响. 中国现代医学杂志. 2018(25): 125-128 .
77.	张雪峰，周星. MRI与CT检查在甘肃会宁地区早期肝癌诊断的对比研究. 国外医学(医学地理分册). 2018(03): 198-200 .
78.	齐杰，高战强，刘树昌，焦杰健，张化冰，冯磊. 磁共振扩散加权成像联合血清肿瘤标志物对诊断早期原发性肝癌价值分析. 临床军医杂志. 2018(09): 1057-1058 .
79.	王海增，陈红娜，宋太民. TACE联合射频消融术治疗巨块型肝癌临床疗效分析. 湖北科技学院学报(医学版). 2018(05): 390-393 .
80.	德庆旺姆，王正，泽永革，赵玉兰，熊伟. 西藏地区肝癌的发病情况及分析. 西藏科技. 2018(10): 39-43 .
81.	梅丽丽，聂磊，曾书娥. 超声造影时间-强度曲线在肝脏恶性肿瘤射频消融中的应用价值. 中华诊断学电子杂志. 2018(04): 226-231 .
82.	游国超，高毅，张强. 复方苦参注射液联合介入疗法治疗原发性肝癌疗效及对患者肝功能影响. 陕西中医. 2018(12): 1722-1724 .
83.	刘艳，温丽娟，钟旭辉. 术后预防性栓塞化疗对乙肝相关小肝癌术后复发风险的影响. 现代消化及介入诊疗. 2018(05): 624-627 .
84.	张先俊，徐莉芳，何忠良. 原发性肝癌患者血清可溶性细胞间黏附分子-1的水平及其与肝纤维化的关系. 解放军医药杂志. 2017(03): 31-34 .
85.	王春阳，庄小捷，张增萍，吕赛平，万祥辉，邹学森. 原发性肝癌患者检测血清同型半胱氨酸的临床意义. 实验与检验医学. 2017(05): 695-696 .
86.	丁韬，魏涧，何旭东. 肝癌根治术后拉米夫定抗病毒治疗对乙型肝炎相关性肝细胞癌患者无瘤生存时间的影响. 临床肝胆病杂志. 2017(08): 1497-1501 . 本站查看
87.	罗丹东，乔安意. 射频消融治疗肝细胞癌的研究进展. 临床肝胆病杂志. 2017(07): 1358-1361 . 本站查看
88.	夏庚，祁飞，杨晋辉，唐映梅，石梦琳，张峻崎. 核因子-κB p65在肝细胞癌中的表达及意义. 临床肝胆病杂志. 2017(12): 2342-2345 . 本站查看
89.	李涛，牛丽娟，李曼，刘文宣，杨磊，马丽霞. 肝细胞癌患者血清miRNA-200c表达变化及其临床意义. 山东医药. 2017(08): 67-69 .
90.	李超，刘志奎，窦常伟，涂康生，杨威. KMT5A对肝细胞癌迁移侵袭的影响及分子机制研究. 实用医学杂志. 2017(16): 2634-2638 .
91.	付锋. HSP90α联合肿瘤标志物在早期肝癌诊断的应用研究. 现代消化及介入诊疗. 2017(06): 856-858 .
92.	刘溪涛，仝林虎，刘立业. 肝脏纤维化指数对原发性肝癌患者术后生存状况的影响. 中华普外科手术学杂志(电子版). 2017(05): 390-392 .
93.	喻晖，乔樵，张财明，郏伟军. 白虎汤治疗原发性肝癌TACE术后患者的临床疗效及预后的影响研究. 中国中西医结合消化杂志. 2017(11): 850-854 .
94.	洪环得，刘建成，颜智琛. CT诊断在鉴别肝细胞癌与肝胆管细胞癌中的应用. 中外医疗. 2016(36): 190-192 .
95.	屈腾箫，屈顺喜. 开滦总医院2004至2015年肝胆科疾病谱变化规律分析. 世界最新医学信息文摘. 2016(87): 204+208 .

Other cited types(28)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2459) PDF downloads(465)

Epidemiological and clinical features of primary liver cancer: an analysis of 236 patients

DOI: 10.3969/j.issn.1001-5256.2016.08.021